CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market. This is very significant since most of the insider trades have been sales for ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

The most impactful development was the rapid success of Moderna's COVID-19 vaccine, Spikevax, which witnessed massive demand during the pandemic. Starting in early 2021, regulatory approvals from ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $40.00 to ...

Moderna has filed complaints in the US and Germany claiming that the mRNA technology used to make Pfizer and BioNTech's Comirnaty vaccine infringes multiple patents that cover its own Spikevax shot.

In December 2020, both Moderna's Spikevax and Pfizer / BioNTech's Comirnaty COVID vaccines received emergency use authorization (“EUA”) in the US. Both used a pioneering new mechanism of ...

Moderna recently faced significant legal challenges with five international lawsuits from Genevant Sciences and Arbutus Biopharma targeting its LNP technology used in products like Spikevax®.

Shares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) have been assigned an average rating of “Hold” from the twenty-four ...

As proven by the success of the Spikevax COVID-19 vaccine, Moderna aims to build on this achievement by expanding into applications for influenza, cancer, and rare diseases. In recent years ...

The new vaccine is an updated version of Moderna's widely-use Spikevax vaccine, which includes sequences from the original Wuhan strain of SARS-CoV-2, as well as from the Omicron BA.1 subvariant.

Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty last year, while Moderna earned $3.2 billion from its vaccine Spikevax, according to ...